0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1423 Views 
0 Saved
0 Vote 1 Contributor1423 Views 0 SavedYou might also be interested in
Dr. S Subramanian, practicing in VS Hospital, Dr. Anita Ramesh at HCG Hospital, and Dr. Saravanan Periasamy in VS Hospital Chennai, are some of the renowned oncologists in Chennai. If you're looking for the best cancer specialists in Chennai, consulting them would be a wise decision. If you're ex....
The risk is so low that it is impossible to read using tables of published health data and statistics. Children do get cancer, but very rarely breast cancer. Statistics will often group women aged 15–39 as “young women” but this is very misleading as the bump in cases begins in women over 20, or eve....
Dear sir, I have suffering from Peptic ulcer from 7 years back and still now, if there any treatment from ur hand so please kindly suggest me.
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.